Table 2.

Effects of increasing week 2 mean calcineurin inhibitors blood concentrations levels as fixed covariates on acute GVHD, chronic GVHD, relapse rate, NRM and OM. Hazard ratios (HR) are given per 100 ng/ml (CSP) or 5 ng/ml (TAC)

Datum	Myeloablative conditioning (n=774)				Nonmyeloablative conditioning (N=407)
	Cyclosporine (n=451)		Tacrolimus (n=323)		Cyclosporine(n=280)		Tacrolimus (n=127)
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Acute GVHD 2–4	0.99 (0.87–1.13)	0.88	1.02 (0.82–1.26)	0.88	0.70 (0.60–0.82)	<0.0001	0.77 (0.53–1.13)	0.18
Acute GVHD 3–4	0.98 (0.71–1.34)	0.88	1.79 (1.12–2.86)	0.02	0.66 (0.49–0.90)	0.008	0.31 (0.11–0.86)	0.02
Chronic GVHD	1.03 (0.88–1.19)	0.74	0.93 (0.70–1.24)	0.61	1.00 (0.83–1.21)	0.99	1.25 (0.86–1.81)	0.25
Relapse	0.82 (0.58–1.16)	0.26	0.91 (0.55–1.51)	0.71	0.96 (0.72–1.28)	0.78	1.25 (0.80–1.96)	0.33
NRM	0.99 (0.76–1.30)	0.94	1.75 (1.17–2.61)	0.007	0.60 (0.41–0.88)	0.008	0.55 (0.19–1.53)	0.25
OM	0.98 (0.84–1.15)	0.80	1.18 (0.90–1.54)	0.22	0.83 (0.71–0.99)	0.03	0.80 (0.56–1.14)	0.21

GVHD – graft vs. host disease, NRM – non relapse mortality, OM – overall mortality